Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme

NCT04224441 is registered in ClinicalTrials.gov with Marco G Paggi, MD, PhD as lead sponsor.

NCT NCT04224441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04224441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
Marco G Paggi, MD, PhD
Phase
Phase 2
Overall status
Unknown status
Start date
December 15, 2019
Completion date
December 15, 2022
Enrollment
41 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, mgmt-unmethylated glioblastoma